Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis

• DOI: 10.1007/s13346-020-00723-6
• Publication Date: 2020-02-14T15:04:21Z
• Authors: Juliana Santos Ro...; Fabiola Garcia Praça; Angelo Luis Caron; Isabella Suzuki; Ana Vitoria Pupo ...; Wanessa Silva Gar...; Jose Orestes Del ...; Marcelo Kravicz; Maria Vitória Lop...
• Keywords: Male; Mice, Inbred BALB C; 0303 health sciences; Imiquimod; Tumor Necrosis Factor-alpha; Down-Regulation; Drug Synergism; Administration, Cutaneous; Tacrolimus; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; Delayed-Action Preparations; Liposomes; NIH 3T3 Cells; Gene therapy; Nanoparticle; Psoriasis; Tacrolimus; Topical application;; Animals; Nanoparticles; Psoriasis; Female; Particle Size; RNA, Small Interfering

Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-α. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-α expression about 7-fold and presenting a synergic effect between the TAC and TNF-α siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time. Graphical abstract.